A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension (PAH) Who Have Completed Study AV-101-002 (IMPAHCT-FUL)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 15 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jun 2024 According to an Aerovate Therapeutics media release, Based upon results from phase 2b portion of IMPAHCT trial, the company, in agreement with the independent study advisory committee, is halting enrollment and shutting down the Phase 3 portion of trial as well as the long-term extension study.
17 Jun 2024 Status changed from recruiting to discontinued, According to an Aerovate Therapeutics media release.
06 Dec 2022 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com